GSK, AstraZeneca plan to harness AI power for drug development from Nvidia's new, $50M-plus supercomputer now under construction
California-based tech company Nvidia is putting down £40 million ($51.7 million) to build one of the world’s most powerful supercomputers — and AstraZeneca and GSK will be among the first to use it.
The machine, named Cambridge-1, is part of Nvidia’s master plan to open a “center of excellence” in the European tech hub. The computer will pack more than 400 petaflops of AI performance, which could be used to streamline drug discovery, CEO Jensen Huang said. A petaflop measures a computer’s processing speed.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.